‘Talk to your CDMO early’ is the advice BioConnection gives to developers of biopharmaceuticals, suggesting that they make a reservation to ensure availability.
Paragon and Passage Bio enter a collaboration agreement to develop a dedicated manufacturing suite at the former’s Maryland facility, as the latter’s gene therapy candidates enter the clinic.
Bluebird bio opens its first wholly owned manufacturing facility to produce lentiviral vectors for the company’s investigational gene and cell therapies.
